• Something wrong with this record ?

Cytomegalovirus-related Complications and Management in Facial Vascularized Composite Allotransplantation: An International Multicenter Retrospective Cohort Study

M. Kauke-Navarro, AC. Panayi, R. Formica, F. Marty, N. Parikh, S. Foroutanjazi, AF. Safi, S. Mardini, RR. Razonable, E. Morelon, B. Gelb, E. Rodriguez, P. Lassus, B. Pomahac

. 2022 ; 106 (10) : 2031-2043. [pub] 20220406

Language English Country United States

Document type Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc22029614

BACKGROUND: There is a paucity of data on the impact of cytomegalovirus (CMV) serostatus and CMV infection on outcomes in facial vascularized composite allotransplantation. METHODS: This international, multicenter, retrospective cohort study presents data on CMV and basic transplant-related demographics, including pretransplant viral D/R serostatus, and duration of antiviral prophylaxis. CMV-related complications (viremia, disease), allograft-related complications (rejection episodes, loss), and mortality were analyzed. RESULTS: We included 19 patients, 4 of whom received CMV high-risk transplants (D+/R-). CMV viremia was noted in 6 patients (all 4 D+/R- patients and 2 D-/R+), mostly within the first-year posttransplant, shortly after discontinuation of antiviral prophylaxis (median 2 mo). CMV disease occurred in 2 D+/R- patients. The high-risk group experienced relatively more rejection episodes per month follow-up. None of D+/R- patients suffered allograft loss due to rejection (longest follow-up: 121 mo). CONCLUSIONS: D+/R- patients were at increased risk of CMV-related complications. Although a higher number of rejections was noted in this group, none of the D+/R- patients lost their allograft or died because of CMV or rejection. Thus, CMV D+/R- face transplantation can likely be safely performed with prophylaxis, active surveillance, and prompt treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22029614
003      
CZ-PrNML
005      
20230113133327.0
007      
ta
008      
230113s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/TP.0000000000004132 $2 doi
035    __
$a (PubMed)35389381
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kauke-Navarro, Martin $u Department of Surgery, Division of Plastic and Reconstructive Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT $u Department of Surgery, Division of Plastic Surgery, Brigham and Women's Hospital, Harvard Medical School; Boston, MA
245    10
$a Cytomegalovirus-related Complications and Management in Facial Vascularized Composite Allotransplantation: An International Multicenter Retrospective Cohort Study / $c M. Kauke-Navarro, AC. Panayi, R. Formica, F. Marty, N. Parikh, S. Foroutanjazi, AF. Safi, S. Mardini, RR. Razonable, E. Morelon, B. Gelb, E. Rodriguez, P. Lassus, B. Pomahac
520    9_
$a BACKGROUND: There is a paucity of data on the impact of cytomegalovirus (CMV) serostatus and CMV infection on outcomes in facial vascularized composite allotransplantation. METHODS: This international, multicenter, retrospective cohort study presents data on CMV and basic transplant-related demographics, including pretransplant viral D/R serostatus, and duration of antiviral prophylaxis. CMV-related complications (viremia, disease), allograft-related complications (rejection episodes, loss), and mortality were analyzed. RESULTS: We included 19 patients, 4 of whom received CMV high-risk transplants (D+/R-). CMV viremia was noted in 6 patients (all 4 D+/R- patients and 2 D-/R+), mostly within the first-year posttransplant, shortly after discontinuation of antiviral prophylaxis (median 2 mo). CMV disease occurred in 2 D+/R- patients. The high-risk group experienced relatively more rejection episodes per month follow-up. None of D+/R- patients suffered allograft loss due to rejection (longest follow-up: 121 mo). CONCLUSIONS: D+/R- patients were at increased risk of CMV-related complications. Although a higher number of rejections was noted in this group, none of the D+/R- patients lost their allograft or died because of CMV or rejection. Thus, CMV D+/R- face transplantation can likely be safely performed with prophylaxis, active surveillance, and prompt treatment.
650    _2
$a antivirové látky $x terapeutické užití $7 D000998
650    _2
$a Cytomegalovirus $7 D003587
650    12
$a cytomegalovirové infekce $x farmakoterapie $7 D003586
650    _2
$a lidé $7 D006801
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a valganciklovir $x terapeutické užití $7 D000077562
650    12
$a vaskularizovaná kompozitní alotransplantace $x škodlivé účinky $7 D063986
650    _2
$a viremie $x farmakoterapie $7 D014766
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Panayi, Adriana C $u Department of Surgery, Division of Plastic Surgery, Brigham and Women's Hospital, Harvard Medical School; Boston, MA
700    1_
$a Formica, Richard $u Department of Surgery, Yale University School of Medicine, Yale New Haven Hospital Transplantation Center, New Haven, CT
700    1_
$a Marty, Francisco $u Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA
700    1_
$a Parikh, Neil $u Department of Surgery, Division of Plastic Surgery, Brigham and Women's Hospital, Harvard Medical School; Boston, MA
700    1_
$a Foroutanjazi, Sina $u Department of Surgery, Division of Plastic Surgery, Brigham and Women's Hospital, Harvard Medical School; Boston, MA
700    1_
$a Safi, Ali-Farid $u Department of Surgery, Division of Plastic Surgery, Brigham and Women's Hospital, Harvard Medical School; Boston, MA
700    1_
$a Mardini, Samir $u Department of Surgery, Division of Plastic and Reconstructive Surgery, Mayo Clinic, Rochester, MN
700    1_
$a Razonable, Raymund R $u Department of Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, MN
700    1_
$a Morelon, Emmanuel $u Department of Transplantation, Edouard Herriot University Hospital, Hospices Civils de Lyon, University Lyon, University of Lyon I, Lyon, France
700    1_
$a Gelb, Bruce $u Department of Surgery, Transplant Institute, NYU Langone Health, New York, NY
700    1_
$a Rodriguez, Eduardo $u Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY
700    1_
$a Lassus, Patrik $u Department of Plastic Surgery, Helsinki University Hospital, Helsinki, Finland
700    1_
$a Pomahač, Bohdan, $u Department of Surgery, Division of Plastic and Reconstructive Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT $d 1971- $7 xx0117402
773    0_
$w MED00010695 $t Transplantation $x 1534-6080 $g Roč. 106, č. 10 (2022), s. 2031-2043
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35389381 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230113 $b ABA008
991    __
$a 20230113133319 $b ABA008
999    __
$a ok $b bmc $g 1883734 $s 1180939
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 106 $c 10 $d 2031-2043 $e 20220406 $i 1534-6080 $m Transplantation $n Transplantation $x MED00010695
LZP    __
$a Pubmed-20230113

Find record

Citation metrics

Archiving options